BENJAMIN YEBOAH: Open Payments
NPI 1174705636 · NEW HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$749 in 28 payments from 14 companies in 2025. Trend: 2023 $319 · 2024 $567 · 2025 $749
Food & beverage: $749
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $235 |
| Lundbeck LLC | 5 | $109 |
| Astellas Pharma US Inc | 3 | $83 |
| AstraZeneca Pharmaceuticals LP | 3 | $69 |
| ABBVIE INC. | 2 | $43 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| Baxter Healthcare | 1 | $25 |
| Novartis Pharmaceuticals Corporation | 1 | $24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
Products named: Wegovy, REXULTI, Veozah, VRAYLAR, INSPIRE, INGREZZA, Hillrom - Carnation Ambulatory Monitor, LEQVIO.
Industry payments across CT — which companies pay providers there.
